Table 1 Clinical characteristics
From: Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis
Baseline demographics | Discovery cohort | Validation cohort 1 | Validation cohort 2 | |||
|---|---|---|---|---|---|---|
lcSSc-PAH | lcSSc-no PAH | lcSSc-PAH | lcSSc-no PAH | lcSSc-PAH | lcSSc-no PAH | |
Age (year) | n = 13 | n = 16 | n = 23 | n = 12 | n = 11 | n = 18 |
Mean (SD) | 65 (7.4) | 50 (14) | 66 (8.6) | 54 (17.8) | 66 (9.4) | 62 (8.5) |
Median (range) | 65 (56–81) | 57 (25–70) | 64 (52–85) | 52 (26–76) | 66 (52–81) | 63 (46–79) |
Sex | ||||||
Female, % (n) | 92% (12) | 87.5% (14) | 83% (19) | 92% (11) | 100% (11) | 83% (15) |
Male,% (n) | 8% (1) | 12.5% (2) | 17% (4) | 8% (1) | 0% (0) | 17% (3) |
mPAP (mmHg) | ||||||
Mean (SD) | 46 (9.1) | – | 42 (12.3) | – | 40 (10.8) | – |
Median (range) | 45 (34–68) | – | 43 (26–69) | – | 42 (25–54) | – |
mPCWP (mmHg) | ||||||
Mean (SD) | 10 (2.7) | – | 10 (4.3) | – | 10 (3.2) | – |
Median (range) | 11 (4–14) | – | 11 (1–15) | – | 9 (5–15) | – |
PVR (Woods units) | ||||||
Mean (SD) | 9 (4.9) | – | 8 (5.3) | – | 8 (4.1)a | – |
Median (range) | 8 (5–24) | – | 6 (3–27) | – | 7 (3–13)a | – |
ILD (Dx by HRCT) | ||||||
Positive, % (n) | 7% (1) | – | 13% (3) | – | 0% (0) | – |
Negative, % (n) | 83% (12) | – | 87% (20) | – | 100% (11) | – |
Treatment | ||||||
Treated, % (n) | 0% (0) | – | 48% (11) | ≈ | 100% (11) | – |
Untreated, % (n) | 100% (13) | – | 52% (12) | – | 0% (0) | – |
BNP (pg/mL) | ||||||
Mean (SD) | 261 (313) | – | 411 (494) | – | – | – |
Median (range) | 140 (42–1054) | – | 148 (12–1630) | – | – | – |
Date of sample | ||||||
At time of RHC, % (n) | 100% (13) | – | 91% (21) | – | 36% (4) | – |